德視佳國際眼科有限公司(EuroEyes)是提供視力矯正的主流眼科集團之一，已于10月15日成功完成了其股票在香港聯合交易所有限公司(“香港聯交所”)主板的上市。全球發售所得款項總額為5.95億港元(包括超額配股權)。

With an issue price of 7,50 Hong Kong dollars, the first exchange rate was 14,20 Hong Kong dollars, about 90 percent higher.

發行價為7.50港元，首次兌換價為14.20港元，約高90%。

With the proceeds from the IPO, EuroEyes plans above all to build clinics in major Chinese cities such as Chengdu and Chongqing, make possible acquisitions of clinics in Europe and strengthen its marketing activities.

借助首次公開募股的收益，德視佳眼科首先計劃在成都和重慶等中國主要城市開設新診所，并加強其市場活動。

"In China, there is a huge need for vision correction. According to a market analysis, almost 90 percent of young people are severely nearsighted. We expect 655 million people in 2023. Presbyopia, which is corrected with a trifocal lens, also plays an important role," says Dr. J?rn S. J?rgensen, founder, chairman and CEO of EuroEyes.

“在中國，人們對視力矯正有很大的需求。根據市場分析，將近90%的年輕人是近視眼。我們預計2023年將有6.55億人。隨著中國人口的日益老齡化，用三焦點晶體矯正中老年人的老花眼也將扮演重要的角色來幫助到中國人民”，德視佳眼科創始人，董事長兼首席執行官約根森博士說道。

The Group has established itself as a high-end provider of surgical vision correction in China. "Our unique selling points include the excellent reputation of German ophthalmology, the large number of operations performed, the early use of modern technologies, the quality and comfort of services, customer satisfaction and the outstanding location of the clinics in the major cities," says Dr. J?rgensen.

德視佳眼科集團已經成為中國視力矯正的高端集團。“我們獨特的特點包括德國眼科手術的卓越聲譽、大量的手術量、最早使用的現代眼科技術、服務的質量和舒適性、客戶滿意度以及主要城市診所的優越地理位置。”約根森博士介紹道。

"We have chosen Hong Kong as our stock exchange location because our future growth is mainly in China and we can finance our expansion from the IPO," says Dr. Markus Braun, CFO of EuroEyes.

德視佳EuroEyes的首席財務官Markus Braun博士說：“我們之所以選擇中國香港作為我們的證券交易所在地，是因為我們的未來增長主要集中在中國，我們可以通過IPO籌集資金。”

In the initial public offering, 79,334,000 offer shares were issued by EuroEyes, of which 71,400,000 offer shares were for its international private placement to professional investors and the remaining 7,934,000 shares were for its Hong Kong public offering. Trading of the EuroEyes share on the SEHK started on 15 October 2019. The public offering in Hong Kong started on 30 September 2019 and finished on 8 October 2019. The offer price and the final allocation were announced on 14 October 2019.

在首次公開募股中，德視佳EuroEyes發行了79,334,000股的發行股份。其中71,400,000股發行是針對專業投資者的國際私募發行，其余7,934,000股則是其在香港的公開發行。德視佳EuroEyes的股份于2019年10月15日開始在聯交所買賣。香港公開發售于2019年9月30日開始，并于2019年10月8日完成。報價和最終分配于2019年10月14日宣布。

BOCI Asia Limited acted as global coordinator for the listing. BOCI Asia Limited, China Securities (International) Corporate Finance Company Limited and Fosun Hani Securities Limited acted jointly as bookrunners and lead managers. Eversheds Sutherland was the Hong Kong and German legal adviser to EuroEyes in its listing.

中銀國際亞洲有限公司擔任上市的全球協調人。中銀國際亞洲有限公司，中國證券(國際)企業融資有限公司和復星證券有限公司共同擔任賬簿管理人和牽頭經辦人。Eversheds Sutherland是德視佳EuroEyes上市的中國香港和德國法律顧問。

EuroEyes International Eye Clinic Limited is a Cayman Islands incorporated company with significant business in Denmark, Germany and China. In terms of sales, the company ranks first in the market for modern refractive laser and lens surgery (excluding PRK and LASEK) in Germany and second in Denmark. The Group was the first foreign provider of surgical vision correction in the People's Republic of China (besides those from Hong Kong, Macau and Taiwan). EuroEyes has a total of 15 locations in Germany, including its headquarters in Hamburg, 6 locations in China, including Shanghai and Beijing, and a further 5 locations in Denmark.

德視佳國際眼科集團是一家在開曼群島注冊成立的公司。在丹麥，德國和中國擁有重要業務。就銷售而言，德視佳眼科在現代屈光激光和晶狀體手術(不包括PRK和LASEK)市場上在德國排名第一，在丹麥排名第二。該集團是中華人民共和國(除中國香港，中國澳門和中國臺灣地區)首家外國眼科手術視力矯正的德國集團。德視佳眼科EuroEyes在德國共有15個診所，包括其在德國漢堡的總部;在中國的6個診所，包括上海、北京、廣州、深圳和杭州;以及在丹麥的5個診所。

Legal Notice

This information does not constitute a public offering of shares in Germany or Denmark or within any other country of the European Monetary Area ("EEA") or outside Hong Kong.

法律聲明

該信息不在德國、丹麥或歐洲貨幣區(“EEA”)的任何其他國家或中國香港以外的地區公開發行股票。